AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Terminated 116 enrolled Allist Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).

Timeline

Start: 2017-06-01
Primary completion: 2021-05-12
Completion: 2024-01-08

Outcome

Outcome not reported

Stopped: “Indications have been approved for marketing”

Publications

Shi Y, Zhang S, Hu X, Feng J, Ma Z, Zhou J, Yang N, Wu L, Liao W, Zhong D, Han X, Wang Z, Zhang X, Qin S, Ying K, Feng J, Fang J, Liu L, Jiang Y. Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. J Thorac Oncol. 2020 Jun;15(6):1015-1026. doi: 10.1016/j.jtho.2020.01.010. Epub 2020 Jan 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Firmonertinib	Small molecule	40 mg	Oral
Subject	Firmonertinib	Small molecule	80 mg	Oral
Subject	Firmonertinib	Small molecule	160 mg	Oral
Subject	Firmonertinib	Small molecule	240 mg	Oral